Form D · Biotechnology
RevMAb Biosciences, Inc.
South San Francisco, CA · CIK 0001667353
Offering snapshot reported Feb 15, 2018 · SEC filing
- Reported sold
- $2.34M Offering amount: $6M
- Investors reported
- 10 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 10, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 15, 2018 | Initial | $2,342,452 | No comparison | 10 | SEC filing |
| Apr 8, 2016 | Initial | $3,300,000 | No comparison | 30 | SEC filing |
| Apr 8, 2016 | Initial | $1,000,000 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-305697
Source: Form D, filed Feb 15, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Yaohuang Ke | Director, Executive |
| George Lee | Director |
| Dean Tsao | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
870 Dubuque Ave.
South San Francisco, CA, 94080
South San Francisco, CA, 94080